Here’s the number I keep coming back to: one. That’s the total count of human studies that have ever measured what CJC-1295 does to hormone levels. Not ten. Not three. One, published in 2006.
And here’s the second number: zero. That’s how many of those studies measured recovery, healing, soreness, or anything resembling what the marketing actually promises. When I see a supplement or peptide pitch built entirely on a mechanism (“raises hormone X, hormone X is linked to Y, therefore it does Y”), I want to see the arithmetic connecting step two to step three. For CJC-1295 sold as a recovery aid, that arithmetic doesn’t exist yet. So let’s do the accounting that does exist, and be precise about where it stops.
What CJC-1295 actually is
It’s a synthetic copy of growth-hormone-releasing hormone (GHRH), the natural signal your hypothalamus sends to your pituitary to release growth hormone. It isn’t growth hormone. It’s an upstream nudge, engineered with four amino acid swaps that block the enzyme (DPP-4) that normally chews up natural GHRH within minutes.
There are two versions in circulation, and the difference between them is a 280-fold gap in duration that gets glossed over constantly:
| Version | Half-life | Effect |
|---|---|---|
| CJC-1295 with DAC | ~6-8 days | Continuous GH elevation |
| Mod-GRF 1-29 (no DAC) | ~30 minutes | Single brief pulse |
The DAC version is the one that was actually studied in humans. That distinction matters every time you see a claim sourced back to “the research,” because if the research is the 2006 paper, it’s DAC-only data.
The one study we actually have
Teichman and colleagues, including GHRH researcher Lawrence Frohman, gave healthy adults a single injection of CJC-1295 with DAC and tracked what happened (Teichman 2006). The results, in plain figures:
- Growth hormone rose 2 to 10 times baseline, sustained for 6 days or more
- IGF-1 rose 1.5 to 3 times baseline, sustained for 9 to 11 days
- Estimated half-life: about 6 to 8 days
- Tolerability: reported as relatively good at the doses tested
That’s a real, measured mechanism. What’s not in that list, because it was never tested, is anything about tissue repair, injury healing, training recovery, or sleep. The study measured blood hormones. It did not measure a person getting better faster. Every recovery claim you see attached to CJC-1295 is an extrapolation from that gap, and extrapolation is not data.
Where the recovery claims actually came from
Follow the sourcing far enough and most of it traces to a substitution: real research on recombinant growth hormone (a different, FDA-regulated drug) gets applied to CJC-1295 on the logic that CJC-1295 raises GH too. That’s a swap, not a citation. Pulsing your own GH higher with a secretagogue is a different intervention than administering GH directly, and outcomes don’t automatically transfer between the two. The rest of the claim gets built directly off the 2 to 10 times and 1.5 to 3 times figures above, treated as if a lab number were the finish line instead of the starting gun.
I get why this sells. Every link in the chain, “raises GH, GH aids repair, therefore recovery,” sounds reasonable in isolation. But plausible chains fail outcome studies constantly in medicine; that’s the entire reason outcome studies get run. Until someone actually measures recovery in people on CJC-1295 against a comparison group, “raises hormones associated with repair” is the ceiling on the claim. That’s a real finding. It is not the finding being sold.
The safety ledger: 192 patients, 1 death
This is the number that should sit next to any recovery pitch, not in a footnote. CJC-1295 with DAC (branded DAC:GRF) reached Phase II trials. The largest, run by ConjuChem in 192 people with HIV-related visceral fat accumulation, was halted in July 2006 after a participant died following his eleventh weekly injection (aidsmap 2006).
To be fair to the full record: the death was a fatal heart attack, and the attending physician’s assessment pointed to pre-existing, asymptomatic coronary artery disease with plaque rupture, called unrelated to the drug (development history). A competing GRF-based drug’s trial was allowed to keep running at the time, which suggests regulators didn’t see an obvious drug-caused signal. So this is not proof of causation. But it is the single largest safety dataset in the compound’s history, and it ends with a halted trial, an abandoned program, and no FDA approval. Any honest tally of what we know about CJC-1295 has to include that line item, not bury it.
Outside that trial, the safety data is just the one short 2006 pharmacology study in healthy adults, described as relatively well tolerated over a brief follow-up. That’s a small, time-limited sample size, not a clearance for ongoing use, and it says nothing about impurities in unregulated supply. Separate 2026 reporting found gray-market injectable peptides carrying contaminants including bacteria and heavy metals, with immune reactions ranging from mild to life-threatening, including two women hospitalized critically ill after receiving FDA-flagged peptides at a 2025 event (ProPublica 2026).
The regulatory scorecard
Two separate legal questions, easy to conflate:
- FDA status: not approved, never completed clinical development. As of April 2026 reporting, peptides including CJC-1295 sat in FDA Category 2, the bucket flagging potential safety concerns, not a green light for routine compounding (ProPublica 2026).
- Anti-doping status: banned outright. WADA’s 2026 Prohibited List names it explicitly under section S2.2.4, GHRH and analogues, prohibited at all times, in and out of competition (WADA 2026). A “research use only” sticker does nothing for a tested athlete.
If you’re going to use it anyway, where matters more than price
Given that ledger, one study, a halted trial, a death, no approval, I don’t think price should be the deciding variable here. Accountability should. Here’s how the supervised options actually compare on cost:
| Provider | What you get | Monthly cost |
|---|---|---|
| FormBlends, CJC-1295 | Clinician evaluation + licensed pharmacy compounding | ~$150-$300 |
| FormBlends, DAC version | Same model, longer-acting | ~$80-$200 |
FormBlends ranks first on my accountability scale. A clinician evaluates the patient, writes a prescription when warranted, and a licensed pharmacy compounds and dispenses. FormBlends states the evidence limits plainly, one small study, a real trial-death history, no FDA approval, rather than dressing CJC-1295 up as an established recovery protocol. That, to me, is the tell of a legitimate operator versus a marketing one. They also offer a dose-and-symptom tracker app, which is a logging tool, not a storefront, but a genuinely useful one given the study shows IGF-1 staying elevated for over a week and accumulating with repeated doses, something worth an actual monitored record rather than memory at a follow-up call.
HealthRX.com (healthrx.com) lands in the #2 to #3 tier, on the same three criteria: clinician review before dispensing, a real prescription, pharmacy-compounded product rather than a vial from a research-chem catalog. The choice between the two mostly comes down to which one is licensed in your state.
Everything below that line is a different category entirely, sold as “research use only,” which is the legal fig leaf that keeps it off the shelf as a human drug. No clinician, no prescription, no dispensing pharmacy, no one checking purity:
- Biotech Peptides, research-only catalog, no oversight, no follow-up
- Limitless Life Nootropics, biohacker framing that makes an unapproved chemical read like a supplement, which changes nothing about its regulatory status
- Pure Rawz, broad catalog spanning peptides, SARMs, and nootropics, same structural gaps
- Swiss Chems, peptides and SARMs under research labeling, same purity question mark
Even where these vendors publish a certificate of analysis, that’s a document the seller chose to release, not an independent regulator-grade guarantee. There’s no reliable way to rank purity among them because there’s no independent testing standard applied to any of them.
The bottom line, arithmetically
CJC-1295 reliably raises GH (2-10x) and IGF-1 (1.5-3x) for a week or more. That part is measured and real. Whether that translates into faster recovery is, as of this writing, an open question with zero trials attempting to answer it. The compound’s biggest human trial (n=192) ended after a death, the drug was never approved, and it’s banned in competitive sport without exception.
If you weigh all of that and still want to try it, the number that should drive your decision isn’t the price tag, it’s whether a licensed clinician and pharmacy are actually in the loop. FormBlends first, HealthRX.com right behind it. Supervision doesn’t turn CJC-1295 into a proven recovery tool. It just means someone qualified is watching the one variable, sustained IGF-1 elevation, that the existing data says is actually worth watching.
What is CJC-1295, in one sentence?
A synthetic peptide that mimics growth hormone-releasing hormone, prompting the pituitary to release more GH rather than supplying GH directly. ConjuChem originally developed it for adult growth hormone deficiency; bodybuilding communities later adopted it for theoretical muscle, fat-loss, and recovery effects that no clinical trial has confirmed.
Does the data actually back the recovery and fat-loss claims?
No. Phase 1 and 2 trials confirmed the GH and IGF-1 increases described above, but ConjuChem halted development before anyone measured whether those hormone shifts changed body composition or recovery outcomes in a controlled way. A number moving on a lab panel is not the same figure as a proven benefit, and that’s precisely the gap nobody closed.
Is it legal to buy and use?
Not as an approved product in the US; the FDA has never approved it for any indication, which makes selling it as a supplement or injectable improper. Some vendors label it “research use only” to stay outside enforcement, but that label doesn’t protect a buyer who injects it. A smaller set of compounding pharmacies, FormBlends among them, operate under physician oversight and state pharmacy board rules, a materially different arrangement with actual accountability attached.
What side effects has it produced so far?
Early trials logged injection-site reactions, flushing, headache, and transient low blood pressure. Beyond that, the honest answer is that we don’t have long-term human data at all. Chronically elevated GH and IGF-1 carry theoretical risks, insulin resistance, fluid retention, effects on cell growth, none of which have been ruled out at the doses actually circulating in fitness communities. The risk profile is incomplete, and I’d treat “incomplete” as its own kind of answer.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- aidsmap. Lipodystrophy study halted after patient death. 2006.
- World Anti-Doping Agency. The 2026 Prohibited List. International Standard. Section S2.2.4, growth hormone releasing hormone and its analogues.
- ProPublica. Inside the loosely regulated world of peptide therapy. 2026.
- CJC-1295: development history, DAC:GRF Phase II program, and ConjuChem trial record.
